Expression of netrin‐1 in uterine serous carcinoma and its association with prognosis
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15513 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Aysegul Ucuncu Kefeli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Radiation Oncology, Kocaeli University, Kocaeli, Turkey. Hauptthemen laut MEDLINE: Netrin-1, Uterine Neoplasms, Biomarkers, Tumor, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kocaeli Üniversitesi.
Abstract (Originalsprache)
Background/Objectives At present, there are few biomarkers used to predict the prognosis of uterine serous carcinoma (USC). Netrin‐1 may be a promising biomarker candidate. We investigated netrin‐1 expression in USC tissues and healthy endometrial tissues to determine its relevance to disease prognosis. Materials and Methods Netrin‐1 expression was examined in the tissues of 48 patients with USC and 30 patients with healthy benign endometrial tissues via immunohistochemistry.
Results
None of the healthy tissues were stained with netrin‐1. In tumor tissues, the overall positivity rate of netrin‐1 was 75%, detected as high expression in 17 patients (35%) and low in 19 (40%). Patients who had tumors with no netrin‐1 expression ( n = 12) had a median overall survival (OS) of 60.0 months (95% confidence interval [CI], 47–98), whereas patients who had tumors with low to strong netrin‐1 expression ( n = 33) had a lower median OS of 50 months, but the difference was not statistically significant (95% CI, 58–108; P = 0.531). Disease‐free survival (DFS) was not statistically significant between the groups (95% CI, 67.7–115.9; P = 0.566). Patients with a tumor diameter ≥2 cm had higher netrin‐1 expression than those with a tumor diameter of 2 cm ( P = 0.027). We did not find any difference in overall and DFS when age, tumor stage, histology, tumor diameter, p53 status, lymphovascular space invasion, myometrial invasion, and lymph node metastasis were compared according to netrin‐1 expression ( P > 0.05).
Conclusion
Netrin‐1 was expressed in USC but not in healthy tissues. Its expression was not associated with OS or DFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Radiation Oncology, Kocaeli University, Kocaeli, Turkey.
- Faculty of Medicine, Department of Pathology, Kocaeli University, Kocaeli, Turkey.
- Division of Medical Oncology, Faculty of Medicine, Department of Internal Medicine, Kocaeli University, Kocaeli, Turkey.
ORCID-Profile: Aysegul Ucuncu Kefeli
Förderung
- Kocaeli Üniversitesi
Zitieren
APA
Ucuncu Kefeli, A., Yaprak Bayrak, B., Betul Tunce, E., Vural, C., Suyusal, I. H., Kefeli, U., & Aksu, M. G. (2024). Expression of netrin‐1 in uterine serous carcinoma and its association with prognosis. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15513
Vancouver
Ucuncu Kefeli A, Yaprak Bayrak B, Betul Tunce E, Vural C, Suyusal IH, Kefeli U, et al. Expression of netrin‐1 in uterine serous carcinoma and its association with prognosis. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15513
BibTeX
@article{UcuncuKefeli2024,
author = {Ucuncu Kefeli, Aysegul and Yaprak Bayrak, Busra and Betul Tunce, Esra and Vural, Cigdem and Suyusal, Ibrahim Halil and Kefeli, Umut and Aksu, Maksut Gorkem},
title = {Expression of netrin‐1 in uterine serous carcinoma and its association with prognosis},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15513}
}
EUVIMED